Table 1. Demographic, clinical, MRI characteristics and current disease-modifying therapies.
| Characteristic | HC | RR-MS & CIS | SP-MS & RR/SP-MS | PP-MS & PR-MS | OND | p-value |
|---|---|---|---|---|---|---|
| Sample Size n | 315 | 411 | 128 | 33 | 82 | – |
| % Female | 61.9% | 69.8% | 74.2% | 54.5% | 69.5% | 0.029 |
| Age, years | 44.1 ± 16 | 42.2 ± 12 | 54.2 ± 9.1 | 54.1 ± 6.4 | 45.0 ± 17 | |
| Disease duration, years | – | 10.6 ± 9.1 | 22.7 ± 11.1 | 15.4 ± 10.6 | 9.5 ± 8.8 | |
| EDSS* | – | 2.0 (1.5) | 6.0 (2.0) | 6.0 (3.0) | – | |
| T2-LV, cm3 | – | 10.5 ± 14 | 19.7 ± 18 | 17.0 ± 20 | – | |
| T1-LV, cm3 | – | 2.2 ± 5.3 | 5.1 ± 7.4 | 2.2 ± 2.5 | – | |
| Sample size | 228 | 383 | 117 | 33 | 72 | |
| Brain volume, cm3 | 1538 ± 92 | 1509 ± 93 | 1417 ± 78 | 1445 ± 86 | 1521 ± 103 | |
| Gray matter volume, cm3 | 782 ± 64 | 757 ± 71 | 701 ± 59 | 717 ± 46 | 760 ± 88 | |
| Interferon-beta-1a | – | 37% | 33% | 17% | – | |
| Interferon-beta-1b | – | 0.7% | – | – | – | |
| Glatiramer acetate | – | 20% | 23% | 26% | – | |
| Natalizumab | – | 14% | 14% | – | – | |
| None § | – | 25% | 23% | 51% | – |
* All continuous variables (age, disease duration, T2-LV, T1-LV) are mean ± standard deviation. For the ordinal EDSS, the median (inter-quartile range) are given.
§ The remainder received other treatments.